Former U.S. officials Gary Locke and Patrick McHenry argue that America must build up domestic biotech capabilities rather than merely containing China. Beijing aims by 2030 to produce 25% of the world's first-in-class drugs—currently produced by the U.S. at seven times that rate—and grow its innova